Global Technology Report

Catheter Precision Inc. (NYSE American: VTAK) Surges with VIVO™ Success

 Breaking News
  • No posts were found

Catheter Precision Inc. (NYSE American: VTAK) Surges with VIVO™ Success

March 19
17:11 2024

Over the recent years, several companies have reached significant milestones, and among the notable achievers is Catheter Precision Inc. (NYSE American: VTAK). The company has witnessed substantial growth, primarily attributable to its flagship product, VIVO™. 

Catheter Precision, Inc. (NYSE American: VTAK), recently spotlighted in “MedTech Outlook”, is showing strength as it trades above its 200-day moving average (DMA). The stock experienced a significant surge of 20.87%, trading 64,684 shares above its 20, 50, and 200-day moving averages (DMA). The stock exhibits a consistent trading pattern, characterized by a strong upward trend that has propelled it into a higher trading range. Keep an eye out for consolidation, which could signal a potential buying opportunity. 

VIVO™ (View into Ventricular Onset) represents a non-invasive 3D imaging system designed to assist physicians in pinpointing the precise location of cardiac arrhythmias prior to procedures. (See EP Lab Digest Case Study Now)  This functionality enhances workflow efficiency and minimizes procedure duration. Additionally, VIVO™ has obtained marketing clearance from the United States Food and Drug Administration and is commercially accessible in the European Union. 

Furthermore, the company has partnered with HHNM Heart Hospital in New Mexico, which serves as one of its distributors for VIVO™. Renowned for offering cutting-edge cardiac services, HHNM Heart Hospital stands as the sole facility in New Mexico exclusively devoted to cardiac care, including LVAD (left ventricular assist device) implants. Since initiating the collaboration with the hospital on September 2021, 175 procedures have been successfully conducted utilizing VIVO™. For each procedure conducted, Catheter Precision earns $1500 from disposables, boasting a gross margin of 90%. Operating on a razor blade model akin to razors and blades, Catheter Precision’s VIVO™ emphasizes device placement and generates revenue primarily from disposables. 

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

Categories